I mere end halvdelen af de rapporterede tilfælde blev behandlingen med proteasehæmmere fortsat eller genoptaget, hvis behandlingen var blevet afbrudt.
In more than a half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued.